N-Glycosylation of Cholera Toxin B Subunit: Serendipity for Novel Plant-Made Vaccines? by Nobuyuki Matoba
PERSPECTIVE
published: 22 December 2015
doi: 10.3389/fpls.2015.01132
Frontiers in Plant Science | www.frontiersin.org 1 December 2015 | Volume 6 | Article 1132
Edited by:
Edward Rybicki,
University of Cape Town, South Africa
Reviewed by:
Markus Sack,
RWTH Aachen University, Germany
Ann Meyers,
University of Cape Town, South Africa
*Correspondence:
Nobuyuki Matoba
n.matoba@louisville.edu
Specialty section:
This article was submitted to
Plant Biotechnology,
a section of the journal
Frontiers in Plant Science
Received: 16 October 2015
Accepted: 29 November 2015
Published: 22 December 2015
Citation:
Matoba N (2015) N-Glycosylation of
Cholera Toxin B Subunit: Serendipity
for Novel Plant-Made Vaccines?
Front. Plant Sci. 6:1132.
doi: 10.3389/fpls.2015.01132
N-Glycosylation of Cholera Toxin B
Subunit: Serendipity for Novel
Plant-Made Vaccines?
Nobuyuki Matoba*
Department of Pharmacology and Toxicology and Owensboro Cancer Research Program of James Graham Brown Cancer
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The non-toxic B subunit of cholera toxin (CTB) has attracted considerable interests
from vaccinologists due to strong mucosal immunomodulatory effects and potential
utility as a vaccine scaffold for heterologous antigens. Along with other conventional
protein expression systems, various plant species have been used as production
hosts for CTB and its fusion proteins. However, it has recently become clear that the
protein is N-glycosylated within the endoplasmic reticulum of plant cells—a eukaryotic
post-translational modification that is not present in native CTB. While functionally active
aglycosylated variants have been successfully engineered to circumvent potential safety
and regulatory issues related to glycosylation, this modification may actually provide
advantageous characteristics to the protein as a vaccine platform. Based on data from
our recent studies, I discuss the unique features of N-glycosylated CTB produced in
plants for the development of novel vaccines.
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INTRODUCTION
Cholera toxin B subunit (CTB) is a non-toxic component of cholera holotoxin, the virulence
factor of Vibrio cholerae (Baldauf et al., 2015). The subunit non-covalently assembles into a
homopentamer structure, which allows for high-affinity interaction with its receptor GM1-
ganglioside present on the surface of mammalian cells. A recombinant, bacterial fermentation-
derived CTB is included in an oral cholera vaccine (Dukoral R©), which has been used in Sweden
since 1991 and granted a marketing authorization throughout the European Union by the
European Commission in 2004 (European Medicines Agency, 2014). Accordingly, CTB represents
one of a few recombinant subunit vaccines currently approved for human use, and it is the
only one that is capable of eliciting an effective immune response via oral delivery. Upon oral
administration, CTB induces a robust antibody response in systemic and mucosal compartments,
thereby neutralizing the holotoxin secreted by the bacteria. Such a strong oral immunogenicity
makes CTB among the most potent mucosal immunogens described to date (Lycke, 2012), and
therefore the protein provides an attractive vaccine platform for the induction of a protective
antibody response to heterologous antigens. Meanwhile, recent studies have shown that CTB
has unique anti-inflammatory activity against immunopathological conditions in allergy and
inflammatory diseases (reviewed in Sun et al., 2010; Baldauf et al., 2015). For example, oral
administration of CTB was shown to mitigate Crohn’s disease in humans (Stål et al., 2010).
A human 60 kD heat-shock protein (HSP60)-derived peptide, p336–351, was chemically linked
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to CTB, and this CTB conjugate protein (p336–351-CTB) was
shown to prevent relapses of uveitis in Behcet’s disease in a phase
I/II clinical trial (Stanford et al., 2004). Collectively, CTB is a
multifunctional mucosal immunomodulatory protein that serves
not only as a cholera vaccine antigen, but also as a molecular
scaffold for novel mucosal vaccines and immunotherapeutics.
Numerous studies have explored such possibilities for various
diseases, which are reviewed elsewhere (Baldauf et al., 2015;
Stratmann, 2015).
Since the late 90’s, a variety of plant species have been used
to constitutively or transiently express CTB and CTB-antigen
fusion proteins, including tobacco (Nicotiana tabacum and N.
benthamiana), potato, rice and tomato, among others (reviewed
in Baldauf et al., 2015). These studies have shown that plant-
expressed CTB proteins formed pentamer structure, retained
binding affinity to GM1-ganglioside and induced relevant
antibody responses upon mucosal immunization. However, we
and others have recently shown that plant-expressed CTB (with
an exception of chloroplast-targeted expression, e.g., Daniell
et al., 2001) is N-glycosylated within the endoplasmic reticulum
(ER) of plant cells, a eukaryotic post-translational modification
not present in the original protein (Mishra et al., 2006; Matoba
et al., 2009; Yuki et al., 2013). While this modification does
not appear to compromise CTB’s principal bioactivity, i.e.,
mucosal immunogenicity, plant-specific glycoforms may lead
to potential safety issues such as hypersensitivity or allergy
(Dicker and Strasser, 2015). It should be noted that plant-specific
glycosylation per se does not necessarily pose an additional
regulatory risk in biopharmaceuticals development unless there is
evidence for product-specific safety and/or efficacy issues found
in preclinical or clinical studies. In fact, no major adverse event
associated with plant-specific glycosylation has been reported for
plant-made biopharmaceuticals that have obtained a regulatory
approval for marketing or emergency use [e.g., carrot cell-
produced β-glucocerebrosidase (Grabowski et al., 2014; Pastores
et al., 2014) and a N. benthamiana-produced H5N1 avian
influenza virus-like particle vaccine (Landry et al., 2010; Ward
et al., 2014), respectively]. Nevertheless, glycosylation would add
a regulatory complication because of glycan heterogeneity. As a
consequence of these theoretical concerns, N-glycosylated CTB
might be viewed inferior to the non-glycosylated counterpart—
unless there is a good reason to keep the modification. Based on
our recent findings, potential advantages of CTB glycosylation for
vaccine development are discussed below.
N-GLYCOSYLATION OF CTB IN PLANTS
The first experimental evidence for CTB glycosylation in planta
was reported by Mishra et al. (2006). The authors showed
that CTB expressed in transgenic tobacco was modified with
a ∼3 kD glycan (per monomer), which was demonstrated by
Schiff ’s test, concanavalin A binding, as well as chemical and
enzymatic deglycosylation. Subsequently, Asn4 of CTB and a
CTB-fusion protein were shown to be glycosylated in transgenic
N. benthamiana (Matoba et al., 2009; Hamorsky et al., 2013)
and transgenic rice (Yuki et al., 2013). Among the two potential
N-glycosylation sites in the amino acid sequence of CTB, one at
the near C-terminus (Asn90-Lys91-Thr92; Figure 1A) was not
glycosylated because the sequon is immediately followed by Pro,
which is known to abolish N-glycosylation (Jones et al., 2005).
Figure 1B shows Asn4-linked glycans modeled in the context of
a CTB crystal structure. It is apparent that the glycosylation site
is exposed and located away from the GM1-ganglioside-binding
pocket, suggesting that the oligosaccharides would not affect
the protein’s receptor binding affinity. This was experimentally
demonstrated in our previous studies based on competitive
GM1-ganglioside-capture enzyme-linked immunosorbent assays
(ELISA) and surface plasmon resonance. Additionally, N.
benthamiana-expressed Asn4-glycosylated CTB (gCTB) showed
acid and thermal stabilities as well as oral vaccine efficacy for the
induction of immunoglobulins (Igs) against cholera holotoxin
that were comparable to those of the non-glycosylated original
protein (Hamorsky et al., 2015).
FIGURE 1 | N-Glycosylation of CTB. (A) Amino acid sequence of CTB from
V. cholerae 569B strain (Protein Data Bank ID: 1FGB). N-Glycosylation
sequons (Asn-X-Thr/Ser) are boxed. (B) Hypothetical structure images
showing CTB homopentamer with high-mannose-type glycans attached to
Asn4 positions. Images, top view on the left and side view on the right, were
created by the Glyprot in silico protein glycosylation tool
(http://www.glycosciences.de/modeling/glyprot/) based on the crystal
structure of CTB (Protein Data Bank ID: 1FGB) and visualized by RasWin
Molecular Graphics (ver. 2.7.5.2). Gray arrows show the positions of
GM1-ganglioside-binding pockets. (C) Percent compositions of glycoforms
attached to Asn4 of CTB, CTB-KDEL, and CTB-MPR-KDEL expressed in N.
benthamiana. Data derived from Matoba et al. (2009), Hamorsky et al. (2013,
2015).
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Figure 1C shows the overall N-glycan profiles of four gCTB
proteins that we have expressed in N. benthamiana, either
constitutively via nuclear transformation or transiently using a
viral vector. Among these, three contained an ER retention signal
(KDEL) at the C-terminus. Unlike high-mannose-rich gCTB-
MPR-KDEL expressed in transgenic N. benthamiana, gCTB-
KDEL produced in transgenicN. benthamiana showed a different
glycan profile, with >80% being plant-specific α(1,3)-fucose
and/or β(1,2)-xylose glycoforms (Hamorsky et al., 2013). The
distinct glycan profiles of these transgenic plant-expressed gCTB
proteins likely reflects their difference in subcellular distribution
in planta; although both contained a KDEL signal sequence, the
fusion protein had a longer extension on the C-terminus due to
the 36-amino-acid MPR domain, which might have facilitated
KDEL receptor recognition for more efficient ER retention.
It is of interest to note that gCTB-KDEL, when transiently
overexpressed using a tobamovirus vector, showed an overall
similar glycan profile to that of the same protein expressed in
transgenic plants (Figure 1C), despite that the two expression
systems had completely different production rate and yield;∼3 g
of gCTB-KDEL were obtained per kg of leaf material in five days
in the transient system (Hamorsky et al., 2015), whereas ∼0.1 g
of the protein were constitutively expressed per kg of transgenic
leaves (Hamorsky et al., 2013). This suggests that the ER retention
efficiency of gCTB-KDEL is similar regardless of the speed of
protein biosynthesis. Meanwhile, gCTB devoid of KDEL showed
a markedly distinct glycan profile with large fractions of complex
glycoforms.
Altogether, the above findings showed the substantial
heterogeneity of N-glycans attached to CTB expressed in plants,
which in turn revealed the limitation of the KDEL-based ER
retention strategy to control such heterogeneity. Cognizant of
potential safety concerns and regulatory complications related
to glycan heterogeneity and/or plant-specific glycoforms, we and
others have developed aglycosylated CTB mutants for vaccine
development; we mutated Asn4 of CTB-KDEL to Ser because
the closely related E. coli heat-labile enterotoxin B subunit
has Ser at the corresponding position (Hamorsky et al., 2013),
while Yuki et al. changed Asn4 of CTB (no KDEL) to Gln
(Yuki et al., 2013). Both of these CTB variants were shown in
animal models to efficiently elicit cholera holotoxin-neutralizing
antibodies upon oral immunization, demonstrating that Asn4
mutations did not affect the protein’s vaccine efficacy. These
results underscore that plant-made aglycosylated CTB variants
can serve as an alternative to the bacteria-produced recombinant
protein currently used in an oral cholera vaccine product.
POTENTIAL ADVANTAGES OF N-GLYCANS
ATTACHED TO CTB
Given that functionally active aglycosylated CTB variants
can be produced in plants, why bother considering the
protein’s N-glycosylation any further? In this regard, recently
we found an interesting function of N-glycosylation for
transient overexpression of CTB in N. benthamiana. When an
aglycosylated CTB variant (N4S-CTB; no C-terminal KDEL)
was expressed using a plant virus vector, the protein induced
strong ER stress and massive tissue damage, resulting in a
poor yield (<10mg of GM1-ganglioside-binding CTB per kg
of leaf material; Hamorsky et al., 2015). In sharp contrast,
gCTB (no KDEL) did not show any significant stress response,
either at gene expression (PDI, BiP, and bZIP60) or macroscopic
levels. Moreover, the protein was very efficiently expressed and
accumulated in a functional pentamer form in leaf tissue. The
expression level reached up to 3 g of gCTB per kg of leaf
biomass, which is among the highest yields for recombinant
protein production in plants reported thus far (Hamorsky et al.,
2015). Based on data obtained by gene expression and protein
ubiquitination analyses, we concluded that the efficient “nursing”
of nascent gCTB polypeptides by lectin chaperones (Molinari,
2007; Aebi, 2013) facilitated the assembly of the pentameric
protein in the ER, thereby mitigating unfolded protein response
that would otherwise lead to strong ER stress and tissue necrosis.
Although the critical role of N-glycosylation in the quality
control of newly synthesized proteins has been well known
(Helenius and Aebi, 2004; Braakman and Bulleid, 2011), the
above study highlighted the significance of such a role for the
efficient bioproduction of recombinant glycoproteins in plant-
based transient overexpression systems.
Thus, a proven advantage of CTB N-glycosylation is the
significant improvement of production yield in plants. Although
the aforementioned complications around glycans still need to be
addressed, these issues have been under extensive investigations
in recent years (Dicker and Strasser, 2015). It is expected that
glycoengineering of host plants will soon generate a superior
expression platform that can provide recombinant glycoproteins
with more uniform, mammalian cell-like glycans (Strasser et al.,
2014). In parallel, advances are being made in refining and
simplifying glycan analysis technologies that can meet regulatory
requirements for biopharmaceutical production (Higgins, 2010;
Shubhakar et al., 2015). Given these efforts in the two front lines
against glycosylation issues, it is the author’s opinion that the
currently perceived inferiority of N-glycosylated CTB is not an
insurmountable challenge to overcome. Nevertheless, a higher
recombinant production yield alone may not sufficiently justify
the development of N-glycosylated CTB for pharmaceutical use
when the non-glycosylated counterpart with comparable efficacy
and safety profiles can be produced in a different production
platform. Below two possible scenarios are discussed that could
represent additional advantages of N-glycosylated CTB over the
non-glycosylated counterpart.
N-Glycans May Alter the B Cell Antigenicity
Profile of CTB
Glycans are generally resistant to humoral immune recognition
due to poor immunogenicity (i.e., lack of T cell epitopes)
and low antigenicity (i.e., high conformational flexibility;
Heimburg-Molinaro et al., 2011; Peri, 2013; Amon et al.,
2014). This is particularly true for “self ” sugar structures
that are found in humans; glycosylation of proteins with
conserved mammalian sugars generally diminishes product
immunogenicity, as discussed in a recent U.S. Food and Drug
Administration (FDA) guidance document for immunogenicity
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assessment of therapeutic protein (FDA, 2014). Many enveloped
viruses take advantage of this unique immunological feature of
carbohydrate molecules by using envelope glycans as a “shield” to
escape from humoral immunity (Vigerust and Shepherd, 2007).
For example, studies have shown that influenza A viruses exploit
N-glycans on the globular head of hemagglutinin, where the
sialic acid-binding site is located, to mask the critical epitopes
recognized by neutralizing antibodies (Tate et al., 2014). Human
immunodeficiency virus type-1 (HIV-1) generates neutralization
escape mutants in each infected individual by changing its
envelope N-glycosylation pattern (Wei et al., 2003). Hepatitis C
virus also uses the glycan shield strategy to reduce the humoral
immunogenicity of envelope proteins and mask neutralizing
epitopes (Helle et al., 2011). These observations point to a
possibility of utilizing N-glycosylation to modify CTB’s antigenic
profile. In line with this notion, a recent study has shown that
N-glycosylation of a malaria antigen (PfAMA1) produced in N.
benthamiana has modified the protein’s antigenicity by shielding
multiple amino acid epitopes from humoral immune recognition
(Boes et al., 2015).
Figure 2A shows the reactivity of a commercial anti-CTB
antiserum to varying concentrations of gCTB and the bacteria-
produced non-glycosylated counterpart. The results clearly show
the masking of a significant portion of CTB’s surface epitopes
that are recognized by the polyclonal antibodies, illustrating the
alteration of the protein’s antigenicity by Asn4-attached glycans.
It is noteworthy that, despite such an antigenic masking effect,
gCTB still raised comparable anti-cholera holotoxin IgA and
IgG responses as native CTB upon oral administration in mice
(Figure 2B; Hamorsky et al., 2015). These results indicate that
Asn4-linked glycans modify the B cell antigenicity profile of
CTB without affecting the protein’s overall immunogenicity.
Accordingly, one testable hypothesis based on these findings
is that the glycans may redirect antibodies to recognize CTB’s
structural domains that are away from the glycosylation site, such
as the foreign antigen moiety in the case of CTB-antigen fusions.
We have previously observed that N. benthamiana-expressed
CTB-MPR, an Asn4-glycosylated CTB-fusion vaccine candidate
against HIV-1, could generate a measurable vaginal IgA response
to the HIV-1 antigen in intranasally immunized mice, which
FIGURE 2 | Immune-related effects of N-glycans attached to CTB. The potential impacts of Asn4-glycans on humoral immunity (A, B) and dendritic cell-specific
intracellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) binding (C, D) are shown. (A) Reactivity of a commercial polyclonal anti-CTB antibody product (List
Biological Laboratories) to native CTB (Sigma-Aldrich) and Asn4-glycosylated CTB expressed in N. benthamiana (gCTB; no C-terminal KDEL attached). An ELISA
plate was coated with GM1-ganglioside, to which varying concentrations of native CTB or gCTB were added. The receptor-bound CTB or gCTB were detected by
incubation with the polyclonal antibodies followed by anti-goat IgG secondary antibodies, as described previously (Hamorsky et al., 2015). Native CTB and gCTB have
a comparable affinity to GM1-ganglioside (Hamorsky et al., 2015). The anti-CTB antibodies recognized native CTB significantly better than gCTB, suggesting antigenic
masking or a “glycan shield” effect by Asn4 glycans. **P < 0.01; ***P < 0.001; Two-way repeated measures analysis of variance (ANOVA) with Bonferroni’s posttest
(GraphPad Prism 5). (B) Serum and Fecal anti-cholera holotoxin antibody titers of C57bl/6 mice orally immunized with native CTB or gCTB (3µg per mouse, twice at a
2-week interval; graphs adapted from Hamorsky et al., 2015, under the Creative Commons Attribution License). (C) DC-SIGN-binding activity of gCTB and an
aglycosylated plant-made CTB (N4S-CTB). An ELISA plate was coated with varying concentrations of gCTB, gCTB produced in plants treated with kifunensin (Kif) or
N4S-CTB, to which a human DC-SIGN-Fc fusion (Sino Biological) was added. The bound DC-SIGN was detected with an anti-human IgG Fc secondary antibody. (D)
gCTB’s binding to cell-surface DC-SIGN. Raji cells expressing DC-SIGN were incubated with Alexa Fluor® 488-labeled N4S-CTB-KDEL, gCTB, or gCTB (Kif) at a final
concentration of 10µg/ml, and analyzed by flow cytometry. **P < 0.01, ***P < 0.001; One-way ANOVA with Bonferroni’s multiple comparison test (GraphPad Prism
5). Graphs adapted from Hamorsky et al. (2015), under the Creative Commons Attribution License.
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seemed to be more effective than that induced by E. coli-derived
CTB-MPR although immunization regimens and immunogen
qualities in those studies were not comparable (Matoba et al.,
2004, 2006, 2009). If this observation is confirmed in a side-by-
side comparison study, it will provide an important implication
for CTB fusion-based vaccine development because the CTB
domain tends to be more immunodominant than bystander
antigens fused to the scaffold (Matoba et al., 2006). Hence, N-
glycosylated CTB may serve as a superior vaccine platform to
the non-glycosylated counterpart for the induction of a better
antibody response to genetically or chemically fused antigens.
N-Glycans May Enhance the
Antigen-Targeting Ability of CTB via
Interaction with C-Type Lectin Receptors
Complex sugars present on microorganisms, cell surfaces and
glycoconjugates have a capability to elicit unique signals in the
immune system by interacting with C-type lectin receptors.
These carbohydrate-binding receptors are abundantly expressed
on innate immune cell membranes, most notably antigen
presenting cells such as dendritic cells and macrophages
(Drickamer and Taylor, 2015). Since C-type lectin receptors
are endocytic, glycosylated antigens are internalized after
binding to the receptors and subsequently presented on major
histocompatibility complex (MHC) class I and II molecules.
Antigen presenting cells can then activate effector or regulatory
T cell responses in cooperation with other co-stimulatory signals.
An early study has shown that mannosylated peptides and
proteins were efficiently taken up by dendritic cells via mannose
receptors, a type of C-type lectin receptors, resulting in 200–
10,000 times more efficient antigen presentation to T cells
than non-mannosylated counterparts (Tan et al., 1997). Given
this, a number of studies have attempted to exploit C-type
lectin receptors to efficiently deliver and present antigens to
T cells (Apostolopoulos et al., 2013; Lepenies et al., 2013;
van Kooyk et al., 2013; Sedaghat et al., 2014). For instance,
oligomannose-coated liposome was shown to be capable of
delivering encapsulated protein antigens to the MHC class I
and class II pathways in antigen presenting cells and thereby
generating antigen-specific cytotoxic T cells and type 1 helper T
cells (Kojima et al., 2013). These findings provide an implication
for the potential use of N-glycosylated CTB.
Among different C-type lectin receptors expressed on
dendritic cells, dendritic cell-specific intracellular adhesion
molecule 3-grabbing non-integrin (DC-SIGN) is a major
receptor that recognizes mannose-containing glycans. We tested
if gCTB could bind to DC-SIGN using ELISA and flow
cytometry. The results demonstrated that gCTB is capable of
binding to recombinant and cell surface-expressed DC-SIGN
(Figures 2C,D; Hamorsky et al., 2015). Notably, gCTB’s binding
affinity to DC-SIGN was significantly enhanced to a nanomolar
level when the protein was produced in plants treated with
the class I α-mannosidase inhibitor kifunensin, which restricts
N-glycans to be high-mannose types (Figures 2C,D; Hamorsky
et al., 2015). Such a high affinity to DC-SIGN is considered
sufficient for dendritic cell targeting, internalization and cross
presentation (Srinivas et al., 2007; Singh et al., 2009). Taken
together, these findings lead to another testable hypothesis that
N-glycosylation may enhance the antigen-targeting capabilities
of CTB fusion proteins via DC-SIGN and other C-type lectin
receptors. Particularly, the ability of C-type lectin receptors to
cross-present antigens on the MHC class I molecule will broaden
the potential utility of gCTB for vaccine development.
CONCLUDING REMARKS
The above two proposed scenarios highlight howN-glycosylation
of CTB may facilitate the protein’s utility as a vaccine
scaffold. Glycoengineering of N-glycans by genetic or chemical
approaches may enhance such potentials, especially by focusing
on high-mannose-type glycans since these glycoforms per
se are generally not immunogenic in mammalians. Hence,
for mucosal antibody induction these glycans may effectively
guide B cells to recognize critical epitopes of CTB-antigen
fusion proteins. On the other hand, high-mannose-glycans
may facilitate the targeting of CTB-antigen fusion to C-type
lectin receptors on antigen presenting cells, providing a new
strategy to induce antigen-specific T cell responses. However, an
important question remains to be addressed for the C-type lectin-
targeting strategy; that is, whether glycosylation of CTB may
or may not modify the protein’s intrinsic immunomodulatory
activity. As described above, CTB was shown to exhibit
anti-inflammatory and immunosuppressive activities under
certain conditions. Depending on how antigen presenting cells
respond upon stimulation with N-glycosylated CTB, vaccine
development based on the glycosylated molecular scaffold should
be aimed at either effector (e.g., for cancer and infectious
diseases) or regulatory (e.g., for allergy and autoimmune
disorders) T cell responses, perhaps in combination with
appropriate co-stimulatory molecules such as cytokines and toll-
like receptor ligands. Because C-type lectin-mediated signaling
is not fully understood (Drickamer and Taylor, 2015), the
above question needs to be carefully addressed for each vaccine
construct. Immunization experiments using N-glycosylated CTB
antigens and corresponding non-glycosylated counterparts will
be particularly useful in addressing these questions. Regardless
of how N-glycosylated CTB instructs the immune system
to respond, the protein seems to open new avenues for
subunit vaccine development; the bottom line is that N-
glycosylated CTB is highly bioproducible in plants, a trait that
can maximize the long-discussed advantages of plant-made
vaccines.
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